Meng-Jen Wu
Overview
Explore the profile of Meng-Jen Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bork F, Greve C, Youn C, Chen S, Leal V, Wang Y, et al.
EMBO Rep
. 2024 May;
25(7):2914-2949.
PMID: 38783164
Neutrophil extracellular traps (NETs) are a key antimicrobial feature of cellular innate immunity mediated by polymorphonuclear neutrophils (PMNs). NETs counteract microbes but are also linked to inflammation in atherosclerosis, arthritis,...
2.
Kline S, Orlando N, Lee A, Wu M, Zhang J, Youn C, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(6):e2309243121.
PMID: 38289950
skin colonization and eosinophil infiltration are associated with many inflammatory skin disorders, including atopic dermatitis, bullous pemphigoid, Netherton's syndrome, and prurigo nodularis. However, whether there is a relationship between and...
3.
Youn C, Pontaza C, Wang Y, Dikeman D, Joyce D, Alphonse M, et al.
Sci Adv
. 2023 Jun;
9(24):eadf8748.
PMID: 37327341
is the leading cause of skin and soft tissue infections and is a major health burden due to the emergence of antibiotic-resistant strains. To address the unmet need of alternative...
4.
Kuo W, Tseng L, Chang C, Chen C, Cheng M, Cheng H, et al.
Diagnostics (Basel)
. 2021 Aug;
11(8).
PMID: 34441396
Predictive metabolic biomarkers for the recurrent luminal breast cancer (BC) with hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-negative are lacking. High levels of -GlcNAcylation (-GlcNAc)...
5.
Wu M, Chen C, Lin T, Liu Y, Tseng L, Cheng M, et al.
Theranostics
. 2021 Aug;
11(16):7779-7796.
PMID: 34335964
The progression of prostate cancer (PCa) to castration-resistant PCa (CRPC) despite continuous androgen deprivation therapy is a major clinical challenge. Over 90% of patients with CRPC exhibit sustained androgen receptor...